Nukkleus received a delisting notice from Nasdaq on November 13, 2024, for failing to maintain minimum requirements of $15 million market value of publicly held shares and $50 million market value of listed securities. The company plans to appeal this determination to a Nasdaq Hearings Panel by November 20, 2024, which will temporarily stay the suspension of trading under symbols NUKK and NUKKW.In a separate development, the company entered into an amended Conversion Agreement with X Group Fund of Funds on November 14, 2024, converting $771,085 of debt into 319,952 shares of common stock. The agreement also includes a warrant with an amended exercise price of $2.41 per share. The securities were issued to accredited investors under Section 4(a)(2) of the Securities Act.

Nukkleus received a delisting notice from Nasdaq on November 13, 2024, for failing to maintain minimum requirements of $15 million market value of publicly held shares and $50 million market value of listed securities. The company plans to appeal this determination to a Nasdaq Hearings Panel by November 20, 2024, which will temporarily stay the suspension of trading under symbols NUKK and NUKKW.In a separate development, the company entered into an amended Conversion Agreement with X Group Fund of Funds on November 14, 2024, converting $771,085 of debt into 319,952 shares of common stock. The agreement also includes a warrant with an amended exercise price of $2.41 per share. The securities were issued to accredited investors under Section 4(a)(2) of the Securities Act.